References
- Taylor JL, Johnson S, Cruz R, et al. Integrating harm reduction into outpatient opioid use disorder treatment settings. J Gen Intern Med. 2021;36(12):3810–3819.
- Food and Drug Administration (FDA). Opioid use disorder; 2018. [cited 2021 Jul 13]. Available from: https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM605959.pdf
- National Institute on Drug Abuse (NIDA). Drugs, brains, and behavior: treatment and recovery; 2020. Available from: https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery. Cited 2021 Jul 14.
- Strain E, Saxon AJ, Hermann R. Opioid use disorder: epidemiology, pharmacology, clinical manifestations, course screening, assessment, and diagnosis; 2018. Available from: http://www.uptodate.com/contents/opioid-use-disorder-epidemiologypharmacology-clinical-manifestations-course-screeningassessment-and-diagnosis. Cited 2021 Jul 13.
- Clark RE, Baxter JD, Aweh G, et al. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015 Oct;57:75–80.
- Ruetsch C, Tkacz J, Nadipelli VR, et al. Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Am J Manag Care. 2017;23(6):e172–e179.
- Han B, Compton WM, Jones CM, et al. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA. 2015 Oct 13;314(14):1468–1478.
- Florence CS, Zhou C, Luo F, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016 Oct;54(10):901–906.
- Murphy SM. The cost of opioid use disorder and the value of aversion. Drug Alcohol Depend. 2020;217:108382.
- Substance Abuse and Mental Health Services Administration. Results from the 2019 national survey on drug use and health: detailed tables. Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2020. Available from: https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR1PDFW090120.pdf Cited 2021 Jul 13.
- Centers for Disease Control and Prevention. 12 month-ending provisional number of drug overdose deaths by drug or drug class; 2021. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm Cited 2021 Jul 13.
- Wakeman SE, Larochelle MR, Ameli O, et al., Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 3(2): e1920622–e1920622. 2020.
- Boyett B. The individualized treatment of opioid use disorder. J Manag Care Spec Pharm. 2019 June;25(6):634–636.
- Lynch FL, McCarty D, Mertens J, et al. Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract. 2014 Aug 14;9(1):16.
- Ronquest NA, Willson TM, Montejano LB, et al. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;9:59–78.
- Larochelle MR, Bernson D, Land T. Medical for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169(3):137–145.
- O’Connor AM, Cousins G, Durand L, et al. Retention of patients in opioid substitution treatment: a systematic review.PLoS One. 2020 [Published 2020 May 14];15(5):e0232086.
- Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–1041.
- Williams AR, Samples H, Crystal S, et al. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2020;177(2):117–124.
- American Society of Addiction Medicine. National practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase: American Society of Addiction Medicine; 2015. Available from: https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf?sfvrsn=0 Cited 2021 Jul 13.
- Maricich YA, Bickel WK, Marsch LA, et al. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr Med Res Opin. 2020;37(2):167–173.
- Budney AJ, Higgins ST. Therapy manuals for drug addiction, a community reinforcement plus vouchers approach: treating cocaine addiction. Rockville: National Institute on Drug Abuse; 1998 13 July 2021. Available from: https://archives.drugabuse.gov/sites/default/files/cra.pdf
- Bolivar HA, Klemperer EM, Colemann SRM, et al. Contingency management for patients receiving medication for opioid use disorder. JAMA Psychiatry. 2021;78(10):1–11.
- Becker SJ, Kelly LM, Kang A, et al. Factors associated with contingency management adoption among opioid treatment providers receiving a comprehensive implementation strategy. Subst Abus. 2019;40(1):56–60.
- Helseth SA, Janssen T, Scott K, et al. Training community-based treatment providers to implement contingency management for opioid addiction: time to and frequency of adoption. J Subst Abus Treat. 2018;95:26–34.
- Rash CJ, DePhillipis D. Considerations for implementing contingency management in substance abuse treatment clinics: the Veterans Affairs initiative as a model. Perspect Behav Sci. 2019;42(3):479–499.
- Christensen DR, Landes RD, Jackson L, et al., Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 82(6): 964–972. 2014.
- Wang W, Gellings Lowe N, Jalali A, et al. Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. J Med Econ. 2021;24(1):61–68.
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14.
- Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 national survey on drug use and health; 2018. Available from: https://www.samhsa.gov/data/sites/default/files/cbhsqreports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf Cited 2021 Jul 13.
- Pharmacy Benefit Management Institute (PBMI). 2018 trends in drug benefit design 13 July 2021. Available from: https://www.pbmi.com/ItemDetail?iProductCode=BDR_2018&Category=BDR
- Wickizer TM, Mancuso D, Huber A. Evaluation of an innovative Medicaid health policy initiative to expand substance abuse treatment in Washington State. Med Care Res Rev. 2012;69(5):540–559.
- Velez FF, Ruetsch C, Maricich Y. Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Expert Rev Pharmacoeconomics Outcomes Res. Jun 2021. https://doi.org/10.1080/14737167.2021.1939687.
- Truven Health Analytics. Use of medication-assisted treatment for opioid use disorders in employer-sponsored health insurance: out-of-pocket costs; 2019 13 July 2021. Available from: https://aspe.hhs.gov/basic-report/use-medication-assisted-treatment-opioid-use-disorders-employer-sponsored-health-insurance-out-pocket-costs
- DePhilippis D, Petry NM, Bonn-Miller MO, et al. The national implementation of Contingency Management (CM) in the department of veterans affairs: attendance at CM sessions and substance use outcomes. Drug Alcohol Depend. 2018;185:367–373.
- Premier Inc. Opioid overdoses costing U.S. hospitals an estimated $11 billion annually 13 July 2021. Available from: https://www.premierinc.com/newsroom/press-releases/opioid-overdoses-costing-u-s-hospitals-an-estimated-11-billion-annually
- Mallow PJ, Belk KW, Topmiller M, et al. Geographic variation in hospital costs, payments, and length of stay for opioid-related hospital visits in the USA. J Pain Res. 2018;11:3079–3088.
- Shah A, Duncan M, Atreja N, et al. Healthcare utilization and costs associated with treatment for opioid dependence. J Med Econ. 2018;21(4):406–415.
- RED BOOK®. IBM Micromedex®, IBM Watson health™. Cited October 13, 2020.
- Campbell ANC, Nunes EV, Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683–690.
- Devlin J, Duprey M, Roberts R, et al. 461: epidemiology, opioid exposure, and outcomes for ICU patients admitted with known opioid use disorder. Crit Care Med. 2018;46(1):214.
- Velez FF, Colman S, Kauffman L, et al. Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Expert Rev Pharmacoecon Outcomes Res. 2021 Feb. ;21(1):69–76. This analysis investigated the impact of reSET-O on HCRU in patients with OUD treated with buprenorphine. The addition of reSET-O resulted in a 60% reduction in hospitalizations and 20% reduction in emergency department visits.
- CMS. Hospital outpatient prospective payment-notice of final rulemaking with comment, CMS-1717-FC 2020 – 2020 NFRM OPPS Cost Statistics Files; 2019. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1717-FC
- McCollister K, Yang X, Sayed B, et al. Monetary conversion factors for economic evaluations of substance use disorders. J Subst Abuse Treat. 2017;81:25–34.
- Office of the Assistant Secretary for Planning and Evaluation. Psychosocial supports in medication-assisted treatment: site visit findings and conclusions; July 2019. Available from: https://aspe.hhs.gov/basic-report/psychosocial-supports-medication-assisted-treatment-site-visit-findings-and-conclusions Cited 2021 Jul 13.
- Texas Health and Human Services. Evaluation of Medicaid spending and outcomes for substance use disorder treatment; 2017. [cited 2021 Jul 13]. Available from: https://hhs.Texas.gov/sites/default/files/documents/laws-regulations/reports-presentations/2017/substance-abuse-disorder-treatment-nov-2017.pdf
- Bureau of Labor Statistics. CPI - All Urban Consumers - U.S. Medical Care Services 13 July 2021. Available from: https://data.bls.gov/cgi-bin/surveymost
- Stevens JP, Wall MJ, Novack L, et al. The critical care crisis of opioid overdoses in the United States. Ann Am Thorac Soc. 2017;14(12):1803–1809.
- Center for Substance Abuse Treatment. Substance abuse: clinical issues in intensive outpatient treatment. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2006 13 July 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK64093/
- Institute for Clinical and Economic Review. Management of patients with opioid dependence: a review of clinical, delivery system, and policy options. Available from: https://icer.org/wp-content/uploads/2020/10/CEPAC-Opioid-Dependence-Final-Report-For-Posting-July-21.pdf Cited July 13, 2021.
- Larson EH, Patterson DG, Garberson LA, et al. Supply and distribution of the behavioral health workforce in rural America. Data Brief #160; 2016. Available from: https://depts.washington.edu/fammed/rhrc/wp-content/uploads/sites/4/2016/09/RHRC_DB160_Larson.pdf Cited 2021 Jul 13.
- World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009 13 July 2021. Available from: https://www.who.int/substance_abuse/publications/9789241547543/en/
- Marsch LA. Digital health and addiction. Curr Opin Syst Biol. 2020;20:1–7.
- Marsch LA, Campbell A, Campbell C, et al. The application of digital health to the assessment and treatment of substance use disorders: the past, current, and future role of the national drug abuse treatment clinical trials network. J Subst Abuse Treat. 2020;112(suppl):4–11.
- Bhatraju EP, Grossman E, Tofighi B, et al. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract. 2017;12(1):7.
- Lo-Ciganic WH, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902.
- Ma J, Bao YP, Wang RJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0094-5.
- Monico LB, Gryczynski J, Mitchell SG, et al. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89–95.
- Shcherbakova N, Tereso G, Spain J, et al. Treatment persistence among insured patients newly starting buprenorphine/naloxone for opioid use disorder. Ann Pharmacother. 2018;52(5):405–414.
- Stone AC, Carroll JJ, Rich JD, et al. Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: safety, dose, retention, and relapse at 6 months. Drug Alcohol Depend. 2018;192:94–97.
- Velez FF, Luderer HF, Gerwien R, et al. Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder. Postgrad Med. 2021 May;133(4):421–427.
- Maricich YA, Gerwien R, Kuo A, Malone DC, Velez FF. Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder, Hospital Practice. 2021;49(5):348-355. DOI: https://doi.org/10.1080/21548331.2021.1974243